Sarepta Therapeutics (NASDAQ:SRPT) Director Stephen Mayo Sells 7,239 Shares

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Stephen Mayo sold 7,239 shares of the company’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the transaction, the director owned 1,765 shares in the company, valued at $30,040.30. This represents a 80.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $16.40 on Friday. Sarepta Therapeutics, Inc. has a 12-month low of $10.41 and a 12-month high of $103.32. The company has a current ratio of 2.32, a quick ratio of 1.48 and a debt-to-equity ratio of 0.73. The company has a market cap of $1.72 billion, a PE ratio of -1.94, a price-to-earnings-growth ratio of 0.25 and a beta of 0.42. The stock has a 50-day moving average price of $19.43 and a 200-day moving average price of $19.98.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The company had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. During the same quarter last year, the company posted $1.90 earnings per share. The firm’s revenue for the quarter was down 32.7% on a year-over-year basis. As a group, equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Wedbush reduced their target price on Sarepta Therapeutics from $34.00 to $29.00 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Wall Street Zen upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Mizuho raised their price objective on Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $32.15.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SRPT. Mercer Global Advisors Inc. ADV boosted its position in Sarepta Therapeutics by 340.7% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 95,752 shares of the biotechnology company’s stock valued at $2,061,000 after buying an additional 74,027 shares during the period. EP Wealth Advisors LLC bought a new position in shares of Sarepta Therapeutics during the fourth quarter valued at about $213,000. Mackenzie Financial Corp boosted its holdings in shares of Sarepta Therapeutics by 17.1% during the fourth quarter. Mackenzie Financial Corp now owns 58,042 shares of the biotechnology company’s stock worth $1,245,000 after purchasing an additional 8,494 shares during the period. Virtus Investment Advisers LLC grew its stake in shares of Sarepta Therapeutics by 166.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 31,741 shares of the biotechnology company’s stock worth $683,000 after purchasing an additional 19,830 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in Sarepta Therapeutics by 251.9% during the 4th quarter. Millennium Management LLC now owns 1,000,109 shares of the biotechnology company’s stock valued at $21,522,000 after purchasing an additional 715,899 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.